Barclays analyst Peter Warendorf lowered the firm’s price target on HealthEquity (HQY) to $110 from $118 and keeps an Overweight rating on the shares. The company preannounced Q4 results “near the top” of previously provided ranges, the analyst tells investors in a research note. The firm believes HealthEquity’s updated cash maturity schedule should increase conviction in its 2026 and 2027 growth.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HQY:
- HealthEquity backs FY26 EPS view $3.87-$3.95, consensus $3.95
- HealthEquity backs FY27 revenue view $1.38B-$1.41B, consensus $1.41B
- HealthEquity reports HSAs as of January 31 10.6M, up 7%
- HealthEquity price target lowered to $110 from $130 at BTIG
- HealthEquity price target lowered to $100 from $120 at Raymond James